156 Participants Needed

Exercise for Chronic Kidney Disease

Recruiting at 1 trial location
DD
JP
Overseen ByJeanie Park, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how exercise can help people with chronic kidney disease (CKD) improve their exercise capacity. Participants will engage in exercise training (also known as cardiac rehabilitation or physical therapy) while taking either sodium bicarbonate or a placebo. A group of healthy individuals will serve as a comparison. The trial aims to understand how exercise affects those with CKD and whether sodium bicarbonate provides additional benefits. This trial may suit people with CKD who don't exercise often and have stable kidney function. As a Phase 2 trial, it measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important research.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as central α-agonists (like clonidine) and immunosuppressive medications (like steroids and biologics). If you are on these medications, you may need to discuss alternatives with your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that exercise is generally safe for people with chronic kidney disease (CKD). In one study, participants handled exercise well, with no exercise-related problems. Another study found that a year-long exercise program improved physical abilities without major safety concerns.

Regarding sodium bicarbonate treatment, studies suggest it can help manage CKD symptoms. It may slow the decline in kidney function and improve blood vessel health. However, it can raise bicarbonate levels in the blood, so monitoring is necessary.

Overall, previous studies have found both exercise and sodium bicarbonate to be safe for people with CKD.12345

Why are researchers excited about this trial's treatments?

Unlike the standard treatments for chronic kidney disease, which often involve medications to manage symptoms and slow disease progression, this approach combines exercise training with either sodium bicarbonate or a placebo. Researchers are excited because exercise training could improve physical fitness and overall health, potentially enhancing kidney function and quality of life. The addition of sodium bicarbonate is particularly intriguing as it might help reduce acidity in the body, a common issue in CKD, offering an extra boost to kidney health. This combination could present a more holistic approach, addressing both physical activity and metabolic balance, which is different from the typical pharmacological treatments.

What evidence suggests that this trial's treatments could be effective for chronic kidney disease?

Research has shown that regular exercise can greatly improve health for people with chronic kidney disease (CKD). It can enhance exercise capacity and may slow disease progression. Exercise might also address other health issues and improve overall quality of life.

In this trial, one group of participants will receive Exercise Training plus Sodium Bicarbonate, which helps manage metabolic acidosis—a condition where the body has too much acid, common in CKD patients. Sodium Bicarbonate can alleviate symptoms like high potassium levels, though its overall impact on kidney function remains mixed. The benefits for physical activity are also unclear. Another group will receive Exercise Training plus Placebo. Combining exercise and sodium bicarbonate might offer various health benefits for people with CKD.35678

Who Is on the Research Team?

JP

Jeanie Park, MD

Principal Investigator

Emory University

Are You a Good Fit for This Trial?

This trial is for sedentary adults with stable chronic kidney disease (CKD) or healthy individuals as controls. CKD participants should have a steady kidney function, normal serum bicarbonate levels, and may have hypertension. Excluded are those with severe obesity, uncontrolled high blood pressure, recent surgery, pregnancy plans, certain heart conditions or metal implants that affect MRI scanning.

Inclusion Criteria

I either have chronic kidney disease or I do not have any kidney disease.
You don't regularly exercise, meaning you exercise for less than 20 minutes, twice a week.
My kidney function is stable and my blood's bicarbonate level is within the normal range.
See 1 more

Exclusion Criteria

You have a condition called metabolic alkalosis.
Your blood has low levels of hemoglobin, which is less than 10 grams per deciliter.
My BMI is over 40.
See 21 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Baseline measurements in healthy participants without CKD will be measured and compared to participants with CKD

1 week
1 visit (in-person)

Treatment

Participants with CKD undergo exercise training for 20-45 minutes, 3 times per week, for 12 weeks, with either sodium bicarbonate or placebo

12 weeks
36 visits (in-person)

Follow-up

Participants are monitored for changes in exercise capacity, MSNA, IL-6, blood pressure, T2water, lean body mass, and exercise pressor reflex

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Exercise Training
  • Placebo
  • Sodium Bicarbonate
Trial Overview The study explores how exercise affects people with CKD compared to healthy controls. It tests whether exercise training or sodium bicarbonate supplementation can improve the body's response to physical activity in CKD patients versus a placebo group.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Exercise Training plus Sodium BicarbonateExperimental Treatment2 Interventions
Group II: Exercise Training plus PlaceboActive Control2 Interventions
Group III: Healthy controlActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials
1,735
Recruited
2,605,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

Aerobic exercise interventions have been shown to improve physical functioning and performance in patients with chronic kidney disease (CKD), with evidence suggesting benefits for blood pressure control, lipid profiles, and mental health.
Despite the known safety and benefits of exercise for CKD patients, many remain inactive, highlighting the need for better assessment and encouragement of physical activity, particularly through low-intensity resistance and aerobic training programs.
Exercise and chronic kidney disease: current recommendations.Johansen, KL.[2022]
Kidney transplantation is the preferred treatment for end-stage renal disease, but patients face increased risks of cancer, infections, and cardiovascular issues post-surgery.
Exercise training is highlighted as a crucial intervention to improve clinical outcomes after kidney transplantation, addressing the common problems of physical inactivity and poor fitness among recipients.
Exercise training in patients after kidney transplantation.De Smet, S., Van Craenenbroeck, AH.[2021]
Exercise training has been shown to significantly improve physical function, fitness, and quality of life in individuals with chronic kidney disease, yet it is not commonly included in standard kidney care programs.
To integrate exercise rehabilitation into kidney care, it is essential to focus on clinically relevant outcomes for patients, implement evidence-based strategies, and treat exercise as a legitimate medical therapy.
Advancing Exercise Science for Better Health Outcomes Across the Spectrum of Chronic Kidney Disease.Bohm, C., Bennett, P., Lambert, K., et al.[2023]

Citations

Effectiveness and Utilization of Cardiac Rehabilitation Among ...For CR completers, median baseline exercise capacity was 6.4 (IQR 5.0–7.7) peak METs for those with CKD and 7.7 (6.4–9.0) METs for those without (P < 0.001).
2.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/24913219/
Exercise training in adults with CKD: a systematic review ...Conclusions: Regular exercise training generally is associated with improved health outcomes in individuals with CKD. Correctly designed exercise rehabilitation ...
Cardiovascular disease risk assessment, exercise training ...We propose a critical and comprehensive review to suggest how to manage patients with chronic kidney disease in clinical practice.
Review of Exercise Interventions to Improve Clinical ...The potential benefits of exercise training in CKD range from slowing disease progression to improving comorbidities and quality of life.
role of exercise training on cardiovascular risk factors and ...The RENEXC trial showed that a combined strength and aerobic training programme significantly reduced albuminuria in patients with CKD G3–G5.21. Effects of ...
Effects of a Renal Rehabilitation Exercise Program in ...Overall, exercise training in this particular study setting and patient population was well tolerated, with no exercise-related adverse events observed. Larger ...
7.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/35944747/
Effect of Long-term Exercise Training on Physical ... - PubMedA 12-month program of in-center aerobic and resistance exercise training was safe and associated with improvements in physical functioning.
Clinical practice guideline exercise and lifestyle in chronic ...This is the first document of its kind to set out the evidence for those people living with kidney disease, including those on haemodialysis and with a kidney ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security